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Plasmodium falciparumAbstract Some novel derivatives of 3-(3-(7-chloroquinolin-4-ylamino)propyl)-1,3-thiazinan-4-one
were synthesized and characterized by their physical and spectral data. All the synthesized com-
pounds were subsequently screened for in vitro antimalarial activity against chloroquine sensitive
strain of Plasmodium falciparum (RKL-2) employing chloroquine as the reference drug. Most of
the synthesized compounds exhibited mild to moderate susceptibilities towards the parasite in
comparison to the standard. It was found that antimalarial activity of 3-(3-(7-chloroquinolin-4-yla-
mino)propyl)-2-(4-bromophenyl)-1,3-thiazinan-4-one was marginally superior than all the com-
pounds evaluated.
ª 2011 Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Malaria is a life-threatening parasitic disease caused by proto-
zoan parasites of the genus Plasmodium. Four species of thePlasmodium viz P. falciparum, P. vivax, P. malariae, and
P. ovale are responsible for the bulk of human malaria cases
globally (http://www.rbm.who.int/) and more recently another
species P. knowlesi infecting humans has been documented
(White, 2008; WHO, 2007). P. falciparum is the most wide-
spread, and causes most severe and potentially fatal malaria
(Talisuna et al., 2004). Over the years chloroquine (CQ) has
remained the drug of choice for the malaria chemotherapy,
because it is effective, less toxic and a cheap drug. The rapid
spread of resistance of P. falciparum towards chloroquine
and other available drugs has become a major health concern
S644 M.K. Kumawat et al.in the tropical and subtropical regions of the world (Sharma,
2007). Therefore, development of novel and effective antima-
larial drug is the better approach to circumvent the problem
faced by clinically used drugs.
The structure–activity relationship studies on 4-aminoquin-
oline antimalarial compounds suggested that the 7-chloro-4-
aminoquinoline nucleus is obligatory for antimalarial activity,
particularly, inhibition of b-haematin formation and accumu-
lation of the drug at the target site (Werbel, 1986; Pandey
et al., 2001; Chou et al., 1980). Shortening (2–3 carbon atoms)
and lengthening (10–12 carbon atoms) of the carbon side chain
in chloroquine (Fig. 1) leads to compounds that remain active
against chloroquine-resistant strains of P. falciparum (Pandey
et al., 2001; De et al., 1998; Solomon et al., 2005; Warhurst,
1981). Solomon et al. (2007) reported a new series of side-chain
modiﬁed 4-aminoquinolines which was found active against P.
falciparum (in vitro) and P. yoelli (in vivo). They also reported
that the basicity of the side chain nitrogen is not very essential
for antiplasmodial activity of 4-aminoquinoline, and the deriv-
ative having [1,3]-thiazinan-4-one ring system with 4-chloro-
phenyl- substitution at the C-2 position attached to the
terminal side chain amino group of 7-chloro-4-aminoquinoline
was 8-fold more potent in antiplasmodial activity as compared
to chloroquine.
These ﬁndings have given impetus to the concept that side
chain modiﬁcation is an attractive strategy for the
development of antimalarial drugs with desirable bioactivity.
Encouraged by these evidences, we presumed that selectively
modifying the pendent amino group with small heterocyclic
systems could modulate the antimalarial activity. Based on this,
title analogues were designed wherein, 7-chloro-4-aminoquino-
line fragment kept rigid and modiﬁcations were made at the C-2
position of a six membered [1,3] thiazinan-4-one ring attached
at the terminal propyl side chain of 7-chloro-4-aminoquinoline.
Accordingly, seven title molecules of 3-(3-(7-chloroquinolin-4-
ylamino)propyl)-2-substituted 1,3-thiazinan-4-one were syn-
thesized and subsequently screened for their in vitro antimalar-
ial activity against laboratory cultured P. falciparum.
2. Materials and methods
2.1. Structural investigation
All chemicals used in the work were procured either from Sig-
ma–Aldrich Corporation, USA or Merck Specialties Pvt. Ltd.,
Mumbai and were used without further puriﬁcation. The inter-
mediate was taken in an open capillary on the Veego-MPI
melting point apparatus and the melting point of the synthe-
sized compound was calculated. The progress of the reactions
was monitored on silica gel-G TLC plate using various solvent
combinations. The spots were detected with iodine vapoursFigure 1 Chloroquine.and illuminated under UV-light. The UV–visible spectra (kmax)
of the synthesized compounds were recorded on UV–visible
spectrophotometer (Shimadzu UV-1700). Infrared spectra
were recorded on an FT-IR Perkin-Elmer spectrometer. The
1H and 13C NMR spectra were recorded at 400 MHz and
100 MHz, respectively on an Avance- 400 Bruker FT-NMR
spectrometer using either DMSO-d6 or CDCl3 as solvent with
tetramethylsilane (TMS) as an internal standard. Mass spectra
were obtained on TOFMS+.
2.2. Antimalarial activity evaluation
All the synthesized compounds were evaluated for in vitro
antimalarial activity against chloroquine sensitive strain
(RKL-2) of P. falciparum (Pf) using 96 well-microtitre plates.
The laboratory adapted strain of Pf was routinely cultured
at 37 C temperature and 5% CO2 environment in RPMI
1640 medium supplemented with 25 mM HEPES, 1% D-glu-
cose, 0.23% sodium bicarbonate and 10% heat inactivated hu-
man serum (Trager and Jensen, 1976). For antimalarial testing
the asynchronous parasites of Pf were synchronized to obtain
only the ring stage parasitized cells by 5% D-sorbitol treat-
ment. For carrying out the assay, the initial ring stage parasita-
emia of 0.8–1.5% at 3% haematocrit in a total volume of
200 lL of medium RPMI-1640 was uniformly maintained. A
stock solution of 5 mg/ml was prepared by dissolving the test
compounds in DMSO and subsequent dilutions were made
with the culture medium. Twenty microlitres of the test com-
pounds at 50 lg/ml concentrations in duplicate wells was incu-
bated with parasitized cell preparation at 37 C and 5% CO2 in
a CO2 incubator. After an incubation period of 36–40 h, the
blood smears were prepared from each well and stained with
3% Giemsa stain. The slides were microscopically observed
and the percent dead rings and schizonts were scored against
100 asexual parasites with respect to the control group.
Chloroquine was used as the standard reference drug.
3. Results and discussion
In the present study, seven new 3-(3-(7-chloroquinolin-4-yla-
mino)propyl)-1,3-thiazinan-4-one derivatives were synthesized
and their antimalarial activity was evaluated in vitro against
chloroquine sensitive P. falciparum.
The target compounds were prepared as outlined inSchemes
1 and 2. The N1-(7-chloroquinolin-4-yl)propan-1,3-diamine
was prepared by aromatic nucleophilic substitution on 4,7-
dichloroquinoline with excess of 1,3-diaminopropane in neat
conditions. The amino group can be transformed to the
thiazinan-4-one skeleton by the reaction of aldehyde and
3-mercaptopropionic acid in the presence of N,N-dicyclohexyl-
carbodiimide (DCC) whereas, DCC was utilized as a dehydrat-
ing agent to accelerate the intramolecular cyclisation, resulting
in faster reaction and improved product yield. The 4-amino-
quinoline derivatives of 2-substituted [1,3]thiazinan-4-ones
were obtained from the N1-(7-chloroquinolin-4-yl)propan-1,3-
diamine, substituted aldehyde and 3-mercaptopropionic acid
in the presence of DCC in anhydrous THF at room
temperature. After completion of the reaction, the desired
products were obtained in excellent yields and purity.
Molecular modiﬁcation of synthesized derivatives was shown
in Table 1.
Scheme 1
Scheme 2
Table 1 Molecular modiﬁcation and in vitro antimalarial activity evaluation of synthesized compounds (test model: chloroquine
sensitive P. falciparum, RKL-2 strain).
Compound R Dosage (lg/ml) Percent dead rings + schizontsa
IIa 50 12.00
IIb 50 9.00
IIc 50 18.50
IId 50 5.50
IIe 50 10.50
IIf 50 8.00
IIg 50 8.00
Chloroquine (Standard) 0.4 50.50
a Mean of two replicates and counted against 100 asexual parasites per replicate.
Synthesis and antimalarial activity evaluation S645
S646 M.K. Kumawat et al.From the structural investigation, FT-IR spectra showed the
stretching frequency range between region 3200–3500 cm1 due
to –N–H stretching, 2800–2950 cm1 due to –C–H stretching
and 1650–1750 cm1 due to –C‚O stretching and 1H NMR
spectra of the compounds showed a singlet at d (ppm) 1.77–
4.56 due to –NH group, a triplet or multiple at d 1.72–4.46
due to –CH2 group and a doublet or multiple at d 5.86–8.80
due to –H, quinoline group, further conﬁrmed the formation
of this class of derivatives. The analytical and spectral data of
the compounds are found in compliance with the structure of
the synthesized compounds.
All the seven synthesized compounds (a–g) presented mild
to moderate activity against chloroquine sensitiveP. falciparum
(RKL-2) strain. Furthermore, these compounds were also
found to exhibit signiﬁcantly inferior activity than chloroquine
in the comparison test (Table 1). However, the compounds with
phenyl-(a), 4-bromophenyl-(c), 2,3-dichlorophenyl-(e) substi-
tution at 2-position of 1,3-thiazinan-4-one ring system attached
with the terminal propyl side chain of 7-chloro-4-aminoquino-
line demonstrate slightly better activity than the compounds
with 4-ﬂuorophenyl-(b), 4-nitrophenyl-(d), pyridine-4-yl-(f),
5-methylfuryl-(g) at the side chain.4. Conclusion
On the basis of the results, it was established that a lipophilic
bulky group at 1,3-thiazinan-4-one ring system attached with
the terminal propyl side chain of 7-chloro-4-aminoquinoline
may be an essential structural requirement for antimalarial
activity of the prepared derivatives. This information will be
useful for further studies in terms of toxicity effect and struc-
tural activity relationship (SAR) to improve their biological
and pharmacological properties in the process of searching
for promising agents with utility in the treatment of malaria.5. Experimental
5.1. Chemistry
The intermediate reaction product (I), N1-(7-chloroquinolin-4-
yl)propan-1,3-diamine (Scheme 1) was prepared according to
the method reported by Madrid et al. (2004) and obtained as
an off-white solid. Seven derivatives (a–g) of 3-(3-(7-chloro-
quinolin-4-ylamino)propyl)-1,3-thiazinan-4-one (Scheme 2)
were prepared as per the method designed by Solomon et al.
(2007).
Compound I: N1-(7-chloroquinolin-4-yl)propan-1,3-dia-
mine: yield 77.40%, mp 96–98 C, Rf value: 0.13 (acetone:eth-
anol = 1:1) spectroscopic analysis: kmax: 263 nm (DMSO); IR
(KBr, tmax, cm
1): 3346, 3333, 3253 (N–H str.), 1190 (C–N
str.), 1090 (C–Cl str.); 1H NMR (DMSO-d6) d (ppm): 1.82
(m, 2H, CH2), 2.65 (t, J= 19.2 Hz, 2H, CH2), 2.76 (br s,
2H, NH2), 3.27–3.32 (t, J= 9.6 Hz, 2H, CH2), 4.32 (br, s,
1H, NH), 6.41–6.44 (d, J= 5.30 Hz, 1H, 3H quinoline),
7.51–7.56 (dd, J= 18.00, 18.00 Hz, 1H, 6H quinoline),
7.61 (d, J= 6.0 Hz, 1H, 5H quinoline), 8.02–8.04 (d,
J= 9.20 Hz, 1H, 8H quinoline), 8.14–8.29 (m, 1H, 2H quino-
line); 13C NMR (DMSO-d6) d (ppm): 39.59, 44.67, 118.47,
127.59, 134.38, 146.89, 151.72, 152.53; MS (m/z): 236.12
[M+H]+.Compound IIa: 3-(3-(7-chloroquinolin-4-ylamino)propyl)-
2-phenyl-1,3-thiazinan-4-one: yield 80.35%, Rf value: 0.75
(acetone:ethanol = 3:1): semi-solid; spectroscopic analysis:
kmax: 262.00 nm (DMSO); IR (CHCl3, cm
1): 3423 (N–H
str.), 1616.6 (C‚O str.), 1090.9 (C–Cl str.); 1H NMR
(DMSO-d6) d (ppm): 1.50–1.86 (m, 2H, CH2), 2.65 (t, J
= 19.2 Hz, 2H, CH2), 2.79–2.84 (m, 2H, CH2), 4.56 (br, s,
1H, NH), 5.53 (s, 1H, CH), 6.24–6.25 (d, J= 4.80 Hz,
1H, 3H quinoline), 7.16–7.18 (d, J= 7.20 Hz, 1H, Ar–H),
7.29–7.34 (d, J= 8.00 Hz, 1H, 6H quinoline), 7.59 (br, s,
1H, 5H quinoline), 8.00–8.02 (d, J= 8.80 Hz, 1H, 8H quin-
oline), 8.30 (m, 1H, 2H quinoline); 13C NMR (DMSO-d6) d
(ppm): 26.20, 36.85, 39.79, 116.79, 123.01, 127.18, 128.79,
129.75, 134.53, 148.30, 151.91, 170.78; MS (m/z): 412.1
[M+H]+.
Compound IIb: 3-(3-(7-chloroquinolin-4-ylamino)propyl)-
2-(4-ﬂuorophenyl)-1,3-thiazinan-4-one: yield 96.20%, Rf va-
lue: 0.79 (acetone:ethanol = 3:1): semi-solid; spectroscopic
analysis: kmax: 261.00 nm (DMSO); IR (CHCl3, cm
1):
3277.1 (N–H str.), 2930.2, (C–H str.), 1611.9 (C‚O
str.),1157.7 (C–F str.), 1091.4 (C–Cl str.); 1H NMR (DMSO-
d6) d (ppm): 1.77–1.86 (dd, J= 10.80,5.60, 2H, CH2), 2.61–
2.65 (t, J= 8.40 Hz, 2H, CH2), 2.82–2.85 (t, J= 6.80 Hz,
2H, CH2), 3.44 (s, 2H, CH2), 4.67 (br, s, 1H, NH), 5.90 (s,
1H, CH), 6.42 (br, s, 1H, 3H quinoline), 7.06–7.15 (m, 1H,
Ar–H), 7.36–7.41 (m, 1H, 6H quinoline), 7.77 (s, 1H, 5H quin-
oline), 7.88–7.90 (m, 1H, 8H quinoline), 8.20–8.30 (d,
J= 49.60 Hz, 1H, 2H quinoline); 13C NMR (DMSO-d6) d
(ppm): 26.30, 36.84, 40.64, 60.91, 117.35, 124.69, 125.14,
129.44, 129.98, 151.75, 160.74, 170.80; MS (m/z): 430.1
[M+H]+.
Compound IIc: 3-(3-(7-chloroquinolin-4-ylamino)propyl)-
2-(4-bromophenyl)-1,3-thiazinan-4-one: yield 69.11%, Rf va-
lue: 0.75 (acetone:ethanol = 3:1): semi-solid; spectroscopic
analysis: kmax: 261.00 nm (DMSO); IR (CHCl3, cm
1):
3297.1 (N–H str.), 2929.4, (C–H str.), 1696.9 (C‚O str.),
1092.9 (C–Cl str.); 1H NMR (DMSO-d6) d (ppm): 1.87 (m,
2H, CH2), 2.20–2.86 (m, 2H, CH2), 3.22–3.40 (d,
J= 72.80 Hz, 2H, CH2), 4.35 (br, s, 1H, NH), 5.79 (s, 1H,
CH), 6.72–6.75 (d, J= 12.80 Hz, 1H, 3H quinoline), 6.83 (s,
1H, Ar–H), 7.46 (m, 1H, 6H quinoline), 7.38–7.76 (dd,
J= 106.40, 86.40 Hz, 1H, 5H quinoline), 8.03 (m, 1H, 8H
quinoline), 8.33–8.59 (d, J= 96.80 Hz, 1H, 2H quinoline);
13C NMR (DMSO-d6) d (ppm): 26.35, 35.29, 40.33, 60.83,
117.84, 121.28, 127.35, 129.06, 143.14, 148.83, 151.78, 169.01;
MS (m/z): 492.0 [M+H]+.
Compound IId: 3-(3-(7-chloroquinolin-4-ylamino)propyl)-
2-(4-nitrophenyl)-1,3-thiazinan-4-one: yield 89.03%, Rf value:
0.80 (acetone:ethanol = 3:1): semi-solid; spectroscopic analy-
sis: kmax: 261.00 nm (DMSO); IR (CHCl3, cm
1): 3264.1 (N–
H str.), 1706.9 (C‚O str.), 1520.1, 1346 (N‚O)2 str.,
1215.8, (C–Cl str.); 1H NMR (DMSO-d6) d (ppm): 1.76 (m,
2H, CH2), 2.80–2.92 (m, 2H, CH2), 3.94–3.97 (t,
J= 10.40 Hz, 2H, CH2), 4.34 (br, s, 1H, NH), 5.86 (s, 1H,
CH), 6.47–6.49 (d, J= 9.20 Hz, 1H, 3H quinoline), 6.89 (s,
1H, Ar–H), 7.44 (m, 1H, 6H quinoline), 7.78–7.79 (d,
J= 8.00 Hz, 1H, 5H quinoline), 8.07–8.14 (m, 1H, 8H quino-
line), 8.32–8.30 (d, J= 8.40 Hz, 1H, 2H quinoline); 13C NMR
(DMSO-d6) d (ppm): 26.34, 35.48, 40.66, 60.64, 117.30, 123.77,
129.21, 146.32, 146.98, 149.55, 151.97, 173.33; MS (m/z): 457.1
[M+H]+.
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2-(2,3-dichlorophenyl)-1,3-thiazinan-4-one: yield 79.95%, Rf
value: 0.43 (acetone:ethanol = 3:1): semi-solid; spectroscopic
analysis: kmax: 262.00 nm (DMSO); IR (CHCl3, cm
1):
3270.2 (N–H str.), 1711.9 (C‚O str.), 1093.1 (C–Cl str.); 1H
NMR (DMSO-d6) d (ppm): 1.79 (m, 2H, CH2), 2.46–2.63
(m, 2H, CH2), 2.85–2.90 (d, J= 16.80 Hz, 2H, CH2), 4.63
(br, s, 1H, NH), 5.59 (s, 1H, Ar–H), 6.41–6.46 (d,
J= 37.60 Hz, 1H, 3H quinoline), 6.90 (s, 1H, Ar–H), 7.40–
7.42 (d, J= 10.80 Hz, 1H, 6H quinoline), 7.60–7.62 (dd,
J= 8.00, 12.00 Hz, 1H, 5H quinoline), 7.98–8.14 (m, 1H,
8H quinoline), 8.30–8.34 (d, J= 16.80 Hz, 1H, 2H quinoline);
13C NMR (DMSO-d6) d (ppm): 26.10, 34.64, 36.84, 46.08,
59.59, 98.84, 117.19, 123.48, 128.51, 129.69, 135.91, 145.82,
149.12, 152.47, 170.82, 173.57; MS (m/z): 482.1 [M+H]+.
Compound IIf: 3-(3-(7-chloroquinolin-4-ylamino)propyl)-
2-(5-methylfuran-2-yl)-1,3-thiazinan-4-one: yield 83.66%, Rf
value: 0.76 (acetone:ethanol = 3:1): semi-solid; spectroscopic
analysis: kmax: 261.00 nm (DMSO); IR (CHCl3, cm
1):
3263.9 (N–H str.), 2926.7 (C–H str.), 1612.7 (C‚O str.),
1091.5 (C–Cl str.); 1H NMR (DMSO-d6) d (ppm): 1.76 (m,
2H, CH2), 2.18–2.19 (d, J= 6.40 Hz, 2H, CH2), 3.83–3.85
(m, 2H, CH2), 4.39 (br, s, 1H, NH), 6.47–6.49 (d,
J= 5.60 Hz, 1H, 3H quinoline), 7.45–7.48 (d, J= 12.80 Hz,
1H, 6H quinoline), 7.77 (s, 1H, 5-methylfuran-2-yl), 8.20–
8.23 (d, J= 9.20 Hz, 1H, 8H quinoline), 8.36–8.37 (d,
J= 5.60 Hz, 1H, 2H quinoline); 13C NMR (DMSO-d6) d
(ppm): 26.99, 34.32, 40.67, 47.99, 56.26, 79.66, 99.03, 117.43,
125.86, 146.95, 151.95, 157.23, 159.92, 168.82, 173.61; MS
(m/z): 416.1 [M+H]+.
Compound IIg: 3-(3-(7-chloroquinolin-4-ylamino)propyl)-
2-(2-pyridin-4-yl)-1,3-thiazinan-4-one: yield 35.88%, Rf value:
0.56 (acetone:ethanol = 3:1): semi-solid; spectroscopic analy-
sis: kmax: 262.00 nm (DMSO); IR (CHCl3, cm
1): 3334.3 (N–
H str.), 1728.7 (C‚O str.), 1090.9 (C–Cl str.); 1H NMR
(DMSO-d6) d (ppm): 1.88–1.90 (d, J= 8.40 Hz, 2H, CH2),
2.57–2.58 (d, J= 5.20 Hz, 2H, CH2), 3.29 (m, 2H, CH2),
4.71 (br, s, 1H, NH), 5.99 (s, 1H, CH), 6.44 (m, 1H, 3H quin-
oline), 6.50–6.52 (m, 1H, pyridin-4-yl), 7.20–7.22 (d,
J= 5.20 Hz, 1H, pyridin-4-yl), 7.44–7.46 (dd, J= 2.00,
2.40 Hz, 1H, pyridin-4-yl), 7.77–7.87 (m, 1H, pyridin-4-yl),
7.82–7.83 (d, J= 2.80 Hz, 1H, 5H quinoline), 8.06–8.10 (dd,
J= 8.00, 6.00 Hz, 1H, 8H quinoline), 8.64–8.63 (d,
J= 4.80 Hz, 1H, 2H quinoline); 13C NMR (DMSO-d6) d
(ppm): 28.10, 34.39, 40.79, 60.23, 79.64, 117.15, 121.87,
122.66, 129.47, 142.76, 149.65, 151.47, 169.03, 170.72, 173.38;
MS (m/z): 413.1 [M+H]+.
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